
Arcus Biosciences (RCUS) Stock Forecast & Price Target
Arcus Biosciences (RCUS) Analyst Ratings
Bulls say
Arcus Biosciences is viewed favorably because the totality of ARC-20 and PEAK-1-linked data suggests casdatifan could be a differentiated, potentially best-in-class HIF-2α backbone in ccRCC, with 44% ORR and 14.5-month mPFS in 2L cas + cabo, 50% cORR and 69% 12-month PFS in 1L cas + zim, and no unexpected safety signals. The outlook is further supported by a dense 2027 catalyst slate, including more mature OS data for cas + cabo, additional readthrough for PEAK-20 and PEAK-21, and early efficacy from combinations with ivonescimab and tivozanib, which could broaden the commercial opportunity across treatment lines. Beyond oncology, quemliclustat, AB102, and other immunology assets add optionality, while the recent financing caused dilution but did not alter the core thesis that Arcus has multiple shots on goal with meaningful strategic partnership interest.
Bears say
Arcus Biosciences is advancing Ph 3 combination trials before completing dose exploration, creating execution risk that the selected dose could leave efficacy on the table, fail to match bidaily administration results, or produce unexpected toxicities. Its use of EPO suppression as a competitive biomarker is also unproven, because the link to tumor response has not been rigorously tested, weakening confidence in the clinical thesis. The company’s heavy concentration in the adenosine pathway adds further downside if efficacy disappoints or safety liabilities emerge, while setbacks in competing adenosine therapies could still undermine the broader market narrative and forecast assumptions.
This aggregate rating is based on analysts' research of Arcus Biosciences and is not a guaranteed prediction by Public.com or investment advice.
Arcus Biosciences (RCUS) Analyst Forecast & Price Prediction
Start investing in Arcus Biosciences (RCUS)
Order type
Buy in
Order amount
Est. shares
0 shares
FAQs About Arcus Biosciences (RCUS) Forecast
Arcus Biosciences (RCUS) Analyst Forecast & Price Prediction
Start investing in Arcus Biosciences (RCUS)
Order type
Buy in
Order amount
Est. shares
0 shares